Sprycel is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with:
• Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
• Accelerated, myeloid, or lymphoid blast-phase Ph+ CML who have shown resistance or intolerance to previous therapy, including imatinib
• Ph+ acute lymphoblastic leukemia (ALL) who have demonstrated resistance or intolerance to prior therapy
Sprycel is also referred to by its drug name, dasatinib, and is a member of the kinase inhibitor class of drugs. It is believed to work in cases of MPN by blocking the activity of several kinase enzymes that are involved in cancer cell proliferation (rapid growth of cancer cells). Blocking their activity can result in the death of cancer cells.
How do I take it?
Prescribing information states that Sprycel is taken orally as a tablet once daily.
Do not stop taking Sprycel suddenly. If you decide to stop taking Sprycel, consult your physician for a plan to reduce your dose gradually. Sprycel should be taken exactly as prescribed by a physician.
The FDA-approved label for Sprycel lists common side effects including bone marrow suppression, fluid retention, diarrhea, headache, musculoskeletal pain, skin rash, shortness of breath, fatigue, nausea, and hemorrhage.
Rare but serious side effects listed for Sprycel include low blood cell counts, potentially fatal bleeding events, heart rhythm abnormalities, heart failure, and fetal harm.
Sprycel may not be appropriate for individuals who are pregnant, breastfeeding, or those with liver issues. Inform your doctor of any existing medical conditions before taking Sprycel.
Sprycel can cause adverse reactions when taken with certain other medications. Tell your doctor about any medications you currently take, including herbal supplements, before taking Sprycel.
For more details about this treatment, visit: